Phase II Study of Dasatinib in Advanced Non-Small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation.
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2011
At a glance
- Drugs Dasatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 06 Sep 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.